CLINICAL_TRIALS
trial_result
· 2024-10-15
Clinical Trial Update: Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer [Phase 2]
Summary
Phase 2 trial evaluating Durvalumab for metastatic colorectal cancer with MSI-H or POLE mutations. Results have been posted (completed 2024-10-15).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Asan Medical Center | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-10-15